We are live on ! Find out more
DTIL icon

Precision BioSciences

86 hedge funds and large institutions have $36.5M invested in Precision BioSciences in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.07% less ownership

Funds ownership: 1.52%1.45% (-0.07%)

4% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 27

11% less call options, than puts

Call options by funds: $8K | Put options by funds: $9K

14% less funds holding

Funds holding: 10086 (-14)

39% less capital invested

Capital invested by funds: $60M → $36.5M (-$23.6M)

67% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 21

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
86
Holders Change
-14
Holders Change %
-14%
% of All Funds
1.37%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
7
Increased
26
Reduced
27
Closed
21
Calls
$8K
Puts
$9K
Net Calls
-$1K
Net Calls Change
-$13K
Name Holding Trade Value Shares
Change
Change in
Stake
GPP
1
Great Point Partners
Connecticut
$6.1M +$4.72M +143,283 +113%
Capital World Investors
2
Capital World Investors
California
$5.06M
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.57M +$402K +12,215 +8%
CA
4
CHI Advisors
New York
$2.61M -$87.8K -2,666 -2%
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$2.19M +$240K +7,278 +8%
Citadel Advisors
6
Citadel Advisors
Florida
$2.14M +$952K +28,879 +44%
Millennium Management
7
Millennium Management
New York
$1.73M -$1.19M -36,176 -32%
JP Morgan Chase
8
JP Morgan Chase
New York
$1.59M +$569K +17,257 +33%
Renaissance Technologies
9
Renaissance Technologies
New York
$1.15M -$59.7K -1,813 -3%
BlackRock
10
BlackRock
New York
$1.12M -$185K -5,603 -10%
OMC
11
OUP Management Company
Pennsylvania
$847K
Marshall Wace
12
Marshall Wace
United Kingdom
$765K +$890 +27 +0.1%
UOC
13
UBS O'Connor
Illinois
$691K +$1.01M +30,528 New
Stifel Financial
14
Stifel Financial
Missouri
$685K -$37.7K -1,144 -4%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$619K +$1.28K +39 +0.1%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$593K +$864K +26,230 New
MSAM
17
Moloney Securities Asset Management
Missouri
$393K -$73K -2,216 -11%
GCP
18
GSA Capital Partners
United Kingdom
$372K +$232K +7,042 +75%
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$355K +$5.5K +167 +1%
ACH
20
ArrowMark Colorado Holdings
Colorado
$288K -$86.3K -2,618 -17%
JAMONY
21
Jacob Asset Management of New York
California
$275K +$43.9K +1,333 +12%
BCM
22
Bridgeway Capital Management
Texas
$241K +$53.7K +1,630 +18%
CWM
23
Curi Wealth Management
North Carolina
$239K +$198 +6 +0.1%
State Street
24
State Street
Massachusetts
$184K +$24.7K +750 +10%
TCM
25
Tekla Capital Management
Massachusetts
$169K

DTIL Hedge Fund Activity: Q1 2023 in Review

86 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q1 2023, worth a combined $36.5M — down 39% from $60M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of DTIL and 7 opened new positions — a net loss of 14 holders — while 27 trimmed existing stakes and 26 added.

The largest buyer was Great Point Partners, adding an estimated $4.72M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.99M sold.

  • 86 institutional investors held Precision BioSciences (DTIL) as of Q1 2023, down from 100 in Q4 2022.
  • Funds reported $36.5M of Precision BioSciences stock for Q1 2023, down 39% quarter-over-quarter.
  • 7 funds opened new Precision BioSciences positions in Q1 2023 and 21 closed out, a net change of -14 holders.
  • The largest Precision BioSciences buyer in Q1 2023 was Great Point Partners, an estimated $4.72M added.
  • The largest Precision BioSciences seller in Q1 2023 was EcoR1 Capital, an estimated $5.99M sold.

Based on aggregated 13F filings for Q1 2023.